Intergroupe Francophone De Cancerologie Thoracique

This study tests whether giving immunotherapy (Cemiplimab) along with chemotherapy (Carboplatin and Paclitaxel) before radiation can help elderly or unfit patients with stage III non-small cell lung cancer live longer without their cancer getting worse. The trial will enroll 152 …

This study tests whether adding an experimental immunotherapy (fianlimab) to standard treatment (cemiplimab plus chemotherapy) can better control pleural mesothelioma, a rare and aggressive cancer of the lung lining. About 126 people who have not yet been treated will receive one…

This phase 2 trial tests a drug called ivonescimab in 38 people with pleural mesothelioma whose cancer has returned after immunotherapy and chemotherapy. The drug works by blocking blood vessel growth and boosting the immune system to fight cancer. The main goal is to see if the …

This Phase 3 trial is testing whether the drug tarlatamab can help people with advanced neuroendocrine carcinoma live longer compared to standard chemotherapy. The study plans to enroll 129 participants who have already received prior treatment. Tarlatamab is given as an infusion…

This Phase 3 trial is testing whether the targeted drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change (MET exon 14 mutation). About 133 patients who have already tried at least one prior trea…